Effectiveness of the levonorgestrel-releasing intrauterine system in the treatment of adenomyosis diagnosed and monitored by magnetic resonance imaging

Bragheto, Aristides Manoel dos Santos; Caserta, Nelson Marcio Gomes; Bahamondes, Luís; Petta, Carlos Alberto

doi:10.1016/j.contraception.2007.05.091

Cited by 125 publications

(75 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…ACCEPTED MANUSCRIPT 11 The suggestion of using LNG-IUS was based on its ability to down-regulate estrogen receptors (ER) in endometrial tissues and its decidualization with subsequent atrophy of the endometrium [12]. In addition, the LNG-IUS has a pain-relieving effect through the reduction of prostaglandin production within the endometrium and induction of adenomyosis foci atrophy [13].…”

Section: Accepted Manuscriptmentioning

confidence: 99%

See 1 more Smart Citation

Levonorgestrel-releasing intrauterine system versus a low-dose combined oral contraceptive for treatment of adenomyotic uteri: a randomized clinical trial

Shaaban¹,

Ali²,

Sabra³

et al. 2015

Contraception

View full text Add to dashboard Cite

Section: Accepted Manuscriptmentioning

confidence: 99%

“…The LNG-IUS group received LNG-IUS (Mirena; Bayer Schering Healthcare AG, Bayer HealthCare, Berlin, Germany), inserted according to the manufacturer's instructions [12]. TVS ascertained proper insertion of the device immediately after insertion.…”

Section: Interventionmentioning

confidence: 99%

Levonorgestrel-releasing intrauterine system versus a low-dose combined oral contraceptive for treatment of adenomyotic uteri: a randomized clinical trial

Shaaban¹,

Ali²,

Sabra³

et al. 2015

Contraception

View full text Add to dashboard Cite

“…Over 70 % of women were satisfi ed with their treatment. Another study enrolled 29 women to receive the LNG-IUD who reported heavy, painful menses and had MRI fi ndings of adenomyosis and followed subjects over time for changes in bleeding pattern and menstrual pain scores [ 6 ]. Heavy menses resolved in all 29 women, with 2 reporting regular menses with normal fl ow, 10 reporting unpredictable spotting, 9 reporting oligomenorrhea, and 8 reporting amenorrhea 6 months after insertion.…”

Section: Abnormal Uterine Bleeding-adenomyosis (Aub-a)mentioning

confidence: 98%

Using Contraceptives for Gynecologic Conditions

Kattan

Burkman

2014

Contraception for the Medically Challenging Patient

View full text Add to dashboard Cite

“…The effects of medical treatments, such as progestin, oral contraceptives or GnRH agonists are transient [3]. Recent studies have demonstrated that levonorgestrel-releasing intrauterine devices are effective for the management of adenomyosis in women with dysmenorrhea and menorrhagia [16,17]. However, the adverse effects of prolonged exposure to progestin treatment, such as headache, breast tenderness, seborrhea, acne and weight gain, may diminish long-term patient satisfaction [18].…”

Section: Discussionmentioning

confidence: 99%

Long-Term Efficacy of Laparoscopic or Robotic Adenomyomectomy with or without Medical Treatment for Severely Symptomatic Adenomyosis

Chong

Lee

Hong

et al. 2016

Gynecol Obstet Invest

View full text Add to dashboard Cite

Background/Aims: To determine the long-term efficacy of laparoscopic or robotic adenomyomectomy with or without gonadotropin-releasing hormone (GnRH) for the treatment of severely symptomatic adenomyosis. Methods: Between August 2008 and May 2011, we prospectively observed 33 patients who underwent laparoscopic or robotic adenomyomectomy with uterine artery ligation for the treatment of symptomatic adenomyosis. Seventeen patients (52%) received 3-course GnRH agonist treatment after the adenomyomectomy. Results: The mean operating time was 147.4 ± 52.0 min, and the mean blood loss was 36.1 ± 37.4 ml. Postoperative complications occurred in 5 patients, including 4 cases of febrile morbidity, 1 case of ileus and 1 case of pelvic abscess. Patients had statistically significant symptom relief during the 3-year follow-up period. Four of the 33 patients (12%) showed symptom relapse; 3 patients showed a relapse with dysmenorrhea and 1 patient showed a relapse with menorrhagia. There were no significant differences in terms of therapeutic outcomes between surgical-only and surgical-medical treatment. Conclusion: Laparoscopic or robotic adenomyomectomy was feasible and safe for women with severely symptomatic adenomyosis who requested uterine preservation. Moreover, this procedure provided long-term symptom control, regardless of postoperative GnRH agonist administration.

show abstract

Effectiveness of the levonorgestrel-releasing intrauterine system in the treatment of adenomyosis diagnosed and monitored by magnetic resonance imaging

Cited by 125 publications

References 16 publications

Levonorgestrel-releasing intrauterine system versus a low-dose combined oral contraceptive for treatment of adenomyotic uteri: a randomized clinical trial

Levonorgestrel-releasing intrauterine system versus a low-dose combined oral contraceptive for treatment of adenomyotic uteri: a randomized clinical trial

Using Contraceptives for Gynecologic Conditions

Long-Term Efficacy of Laparoscopic or Robotic Adenomyomectomy with or without Medical Treatment for Severely Symptomatic Adenomyosis

Contact Info

Product

Resources

About